Aaron Mann
I am privileged to be the CEO of Windgap Medical, a privately-held drug delivery company
focused on solutions which simplify, automate, and accelerate the delivery of difficult-to-mix
drugs. Our solutions free patients, families, and complex therapies from the limitations of
current delivery systems. In partnership with leading biopharmaceutical companies, we are
working to bring these solutions to patients.
Previously, I was CEO at Kindeva Drug Delivery, a leading global CDMO to
biopharmaceutical companies, with over 1000 talented colleagues, which was spun out of 3M
in 2020, backed by Altaris Capital Partners. Kindeva's capabilities span inhalation,
transdermal and microneedles, from pre-clinical work, through regulatory processes and
approval, into commercial scale and supply with sites in the US and the UK. Through
COVID and over the course of two years we fully separated the business from 3M and
established a clean, global, modern set of systems and processes.
At 3M, I led the Drug Delivery Systems business, a global leader in the contract formulation,
development, and manufacturing of delivery systems for complex molecules. I also held
responsibility for strategy and business development for the Health Care Business Group,
completing ~$8B of transactions. Key accomplishments include the acquisitions of Acelity
(wound care) and mModal (health IT).
Earlier, I ran corporate development, strategy, and marketing at Phillips-Medisize, a Molex
company. Phillips-Medisize is a global contract designer and manufacturer of drug delivery
and medical device products Golden Gate Capital sold Phillips-Medisize to Molex and Koch
Industries in October 2016. I've also led Operations at Remedi Senior Care, a Centerbridge
Partners portfolio company. Remedi, an institutional pharmacy, was built around a
proprietary high-speed automated dispensing system, serving over 30,000 long-term care
residents from 6 pharmacies 24x7x365.
I began my career at Bain & Company, spending significant time across four continents and
multiple industries and wide range of capabilities. I graduated from the Harvard Business
School and Carleton College.
Aaron Mann
Chief Executive Officer
Windgap Medical
Aaron Mann is the esteemed CEO of Windgap Medical, a privately-held drug delivery company with a focus on simplifying, automating, and expediting the delivery of challenging-to-mix drugs. Under his leadership, Windgap Medical collaborates with leading biopharmaceutical companies to provide solutions that liberate patients, families, and complex therapies from the constraints of current delivery systems.
Previously, Aaron served as the CEO at Kindeva Drug Delivery, a prominent global CDMO for biopharmaceutical companies. Leading a team of over 1000 talented colleagues, he successfully steered the company through its spin-off from 3M in 2020, with backing from Altaris Capital Partners. Kindeva’s comprehensive capabilities encompass inhalation, transdermal, and microneedles, spanning pre-clinical development, regulatory processes, and approval, all the way to commercial scale and supply, with operations in the US and the UK. Over a challenging two-year period, Aaron oversaw the complete separation of Kindeva from 3M, establishing a clean, global, and modern set of systems and processes.
Aaron’s distinguished career includes leadership roles at 3M, where he spearheaded the Drug Delivery Systems business, a global leader in contract formulation, development, and manufacturing of delivery systems for complex molecules. Concurrently, he held responsibility for strategy and business development for the Health Care Business Group, successfully completing approximately $8 billion worth of transactions. Key highlights of his tenure at 3M include the strategic acquisitions of Acelity (wound care) and mModal (health IT).
Prior to 3M, Aaron played pivotal roles in corporate development, strategy, and marketing at Phillips-Medisize, a Molex company, which is a global contract designer and manufacturer of drug delivery and medical device products. During his time at Phillips-Medisize, Golden Gate Capital sold the company to Molex and Koch Industries in October 2016.
Aaron’s extensive leadership experience also extends to his role as Head of Operations at Remedi Senior Care, a Centerbridge Partners portfolio company. Here, he oversaw operations at an institutional pharmacy built around a proprietary high-speed automated dispensing system, catering to over 30,000 long-term care residents from six pharmacies, operating 24x7x365.
Aaron Mann embarked on his career journey at Bain & Company, a global management consulting firm, where he gained invaluable experience working across four continents, diverse industries, and a wide range of capabilities. His educational background includes graduating from the Harvard Business School and Carleton College.